Unknown

Dataset Information

0

Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.


ABSTRACT: Spliceostatin A (SSA) is a stabilized derivative of a Pseudomonas bacterial fermentation product that displays potent anti-proliferative and anti-tumor activities in cancer cells and animal models. The drug inhibits pre-mRNA splicing in vitro and in vivo and binds SF3b, a protein subcomplex of U2 small nuclear ribonucleoprotein (snRNP), which is essential for recognition of the pre-mRNA branch point. We report that SSA prevents interaction of an SF3b 155-kDa subunit with the pre-mRNA, concomitant with nonproductive recruitment of U2 snRNP to sequences 5' of the branch point. Differences in base-pairing potential with U2 snRNA in this region lead to different sensitivity of 3' splice sites to SSA, and to SSA-induced changes in alternative splicing. Indeed, rather than general splicing inhibition, splicing-sensitive microarray analyses reveal specific alternative splicing changes induced by the drug that significantly overlap with those induced by knockdown of SF3b 155. These changes lead to down-regulation of genes important for cell division, including cyclin A2 and Aurora A kinase, thus providing an explanation for the anti-proliferative effects of SSA. Our results reveal a mechanism that prevents nonproductive base-pairing interactions in the spliceosome, and highlight the regulatory and cancer therapeutic potential of perturbing the fidelity of splice site recognition.

SUBMITTER: Corrionero A 

PROVIDER: S-EPMC3049286 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.

Corrionero Anna A   Miñana Belén B   Valcárcel Juan J  

Genes & development 20110301 5


Spliceostatin A (SSA) is a stabilized derivative of a Pseudomonas bacterial fermentation product that displays potent anti-proliferative and anti-tumor activities in cancer cells and animal models. The drug inhibits pre-mRNA splicing in vitro and in vivo and binds SF3b, a protein subcomplex of U2 small nuclear ribonucleoprotein (snRNP), which is essential for recognition of the pre-mRNA branch point. We report that SSA prevents interaction of an SF3b 155-kDa subunit with the pre-mRNA, concomitan  ...[more]

Similar Datasets

| S-EPMC2991248 | biostudies-literature
| S-EPMC87247 | biostudies-literature
2022-12-19 | PXD035346 | Pride
2022-12-02 | GSE208181 | GEO
| S-EPMC2776460 | biostudies-literature
| S-EPMC3209046 | biostudies-literature
| S-EPMC10325889 | biostudies-literature
| PRJNA858674 | ENA
| S-EPMC2397502 | biostudies-literature
| S-EPMC7684319 | biostudies-literature